摘要
目的:研究非小细胞肺癌(nonsmallcelllungcancer,NSCLC)中整合素亚基β5表达的生物学意义及其与血管内皮生长因子(VascularEndothelialGrowthFactor,VEGF)的关系。方法:应用免疫组化法检测102例NSCLC中整合素β5和VEGF的表达水平;78例正常肺组织作为对照组。并将整合素β5与VEGF及肿瘤的各种临床病理特征进行统计学分析。结果:102例NSCLC中,83例(81.37%)整合素β5阳性表达,显著高于正常肺组织37.17%的阳性表达率(P<0.05);85例(83.33%)NSCLC中VEGF阳性表达,其中有80例VEGF与整合素β5共同表达,在统计学上具有显著的正相关(P<0.01);整合素β5的表达与肿瘤的大小、淋巴结是否转移呈有相关性,而同患者的性别、年龄、肿瘤的组织学分类、分级无关。结论:整合素β5的表达促进肿瘤血管的形成,为肿瘤的浸润、转移创造条件,临床上可利用整合素β5作为治疗靶点抗血管生成,从而为肿瘤治疗提供新途径。
Objective:To investigate the significance of integrin beta5 expression in non-small cell lung cancers and its correlation with VEGF. Methods: One hundred and two cases of NSCLC and 78 normal lung tissues as control group were detected beta5 and VEGF with immunohistochemistry. The statistical analyses were taken between integrin beta5 and VEGF, clinicopathological characters. Results:In 102 NSCLC, 83 cases(81.37%) were integrin beta5 positive. The positive rate was much higher than that(37.17%) of normal cases (P<0.05=. Eighty-five cases(83.33%) of NSCLC were of VEGF positive. Among them, 80 cases were integrin beta5 and VEGF co-positive. There was significantly positive relationship between them (P<0.01) . The expression of integrin beta5 was associated with tumor size and lymph node metastasis, but not with patients' sexes, ages, tumor histological types and grades. Conclusion:The expression of integrin beta5 has a significantly improved efficacy in promoting angiogenesis, and then creates the good condition for tumor invasion and metastasis. For NSCLC clinical treatment, integrin beta5 could be as an attractive target to intervene angiogenesis.
出处
《实用临床医学（江西）》
CAS
2005年第6期5-8,共4页
Practical Clinical Medicine
